XML 12 R2.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
ASSETS    
Cash and cash equivalents $ 86,259 $ 110,662
Restricted cash 1,525 1,738
Research and development incentives receivable 4,536 7,139
Prepaid expenses and other current assets 7,681 6,203
Assets held for sale 413 0
Total current assets 100,414 125,742
Property and equipment, net 4,514 7,373
Intangible assets, net 20,366 21,947
Right of use assets, net 3,323 4,384
Other assets 944 881
Total assets 129,561 160,327
Current liabilities:    
Accounts payable 1,800 2,474
Accrued expenses and other current liabilities 7,364 9,525
Deferred income 1,525 1,738
Operating lease liability - current 2,036 1,920
Total current liabilities 12,725 15,657
Non-current liabilities:    
Operating lease liability - non-current 9,952 10,087
Contingent consideration 2,544 2,650
Other non-current liabilities 1,468 1,360
Deferred tax liability, net 391 438
Total liabilities 27,080 30,192
Commitments and contingencies (Note 15)
Stockholders’ equity:    
Ordinary shares, £0.000025 nominal value; 40,348,665 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 40,234,663) 1 1
Additional paid-in capital 393,663 393,474
Accumulated deficit (278,436) (237,664)
Accumulated other comprehensive loss – foreign currency translation adjustments (12,937) (25,868)
Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders 102,377 130,029
Noncontrolling interest 104 106
Total stockholders’ equity 102,481 130,135
Total liabilities and stockholders’ equity 129,561 160,327
Deferred A shares    
Stockholders’ equity:    
Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 63,443) $ 86 $ 86